Zurcher Kantonalbank (Zurich Cantonalbank) Arcus Biosciences, Inc. Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $39 Billion
- Q2 2025
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 35,771 shares of RCUS stock, worth $477,542. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,771
Previous 35,748
0.06%
Holding current value
$477,542
Previous $280,000
3.93%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding RCUS
# of Institutions
208Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$130 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$87.5 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$79.7 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$53.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$49.2 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $963M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...